Physician profile
James D Young
NPI 1619956661
$5,866.45
in general payments reported to CMS, 2019-2025
32 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,833 · 2020: $368 · 2021: $13.27 · 2022: $1,941 · 2023: $18.05 · 2024: $477 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551 · Grant: $125 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.13 |
| Grant | $125.00 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,505.12 | 2021-2022 | |
| Karl Storz Endoscopy-America | $1,220.01 | 2019 | |
| Procept Biorobotics Corporation | $522.03 | 2022-2025 | Aquabeam System, Aquabeam Robotic System |
| Janssen Biotech, INC. | $463.51 | 2019-2025 | Erleada |
| Astellas Pharma US INC | $295.49 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $183.52 | 2019-2024 | |
| Endo Pharmaceuticals INC. | $147.32 | 2019-2020 | |
| Pfizer INC. | $145.83 | 2019-2024 | |
| Abbvie INC. | $125.00 | 2024 | |
| Boston Scientific Corporation | $122.40 | 2019-2024 | Greenlight Xps |
| Dendreon Pharmaceuticals LLC | $105.74 | 2019-2024 | Provenge |
| Antares Pharma, INC. | $92.94 | 2019 | |
| Neotract INC. | $87.97 | 2019 | |
| Innovation Technologies INC | $85.53 | 2024 | Irrisept |
| Allergan, INC. | $80.51 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $73.68 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $70.55 | 2019-2020 | |
| Coloplast Corp | $69.35 | 2019-2020 | |
| Olympus America INC. | $62.44 | 2019-2020 | |
| Travere Therapeutics, INC. | $57.30 | 2019-2020 | |
| Acell, INC. | $57.27 | 2019-2020 | |
| Urogpo LLC | $54.37 | 2019 | |
| Photocure INC | $49.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.98 | 2019-2024 | |
| Zyla Life Sciences, INC. | $36.00 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Amgen INC. | $29.74 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $21.56 | 2025 | Purewick Female External Catheter |
| Cook Medical LLC | $16.04 | 2025 | Litho 150 |
| Tolmar Pharmaceuticals, INC. | $11.79 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$637,739.29 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.